Modeling viral infectious diseases and development of antiviral therapies using human induced pluripotent stem cell-derived systems

Viruses

Volumn 7, Issue 7, 2015, Pages 3835-3856

  Trevisan, Marta ^a   Sinigaglia, Alessandro ^b   Desole, Giovanna ^a   Berto, Alessandro ^a   Pacenti, Monia ^c   Palù, Giorgio ^a,c   Barzon, Luisa ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Antiviral resistance; CRISPR Cas9; Ersonalized therapy; Genetic susceptibility; Genome editing; Hepatitis C virus; Human immunodeficiency virus; Human induced pluripotent stem cells; Patient specific isease model; Viral infection

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; SHORT HAIRPIN RNA; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; ZINC FINGER NUCLEASE; ANTIVIRUS AGENT;

ANTIMICROBIAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CELL DIFFERENTIATION; CYTOMEGALOVIRUS INFECTION; EMBRYONIC STEM CELL; ENCEPHALITIS; ENTEROVIRUS MYOCARDITIS; GENETIC ENGINEERING; GENETIC SUSCEPTIBILITY; HEPATITIS; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS INFECTION; HERPES ZOSTER; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION SENSITIVITY; INFLUENZA; MARKER GENE; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; REVIEW; VIRUS MUTATION; VIRUS MYOCARDITIS; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; DRUG EFFECTS; GENETICS; INDUCED PLURIPOTENT STEM CELL; VIRAL PHENOMENA AND FUNCTIONS; VIROLOGY; VIRUS; VIRUS DISEASES;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; VIRUS DISEASES; VIRUS PHYSIOLOGICAL PHENOMENA; VIRUSES;

EID: 84937510370     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7072800     Document Type: Review

References (110)

1. Heymann, D.L.; Chen, L.; Takemi, K.; Fidler, D.P.; Tappero, J.W.; Thomas, M.J.; Kenyon, T.A.; Frieden, T.R.; Yach, D.; Nishtar, S.; et al. Global health security: The wider lessons from the west African Ebola virus disease epidemic. Lancet 2015, 385, 1884–1901.. [CrossRef]
2. Chapman, S.J.; Hill, A.V. Human susceptibility to infectious disease. Nat. Rev. Genet. 2012, 13, 175–188 [PubMed]
3. Lee, M.N.; Ye, C.; Villani, A.C.; Raj, T.; Li, W.; Eisenhaure, T.M.; Imboywa, S.H.; Chipendo, P.I.; Ran, F.A.; Slowikowski, K.; et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science 2014, 343, 1246980 . [CrossRef] [PubMed]
4. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126, 663–676.. [CrossRef] [PubMed]
5. Bellin, M.; Marchetto, M.C.; Gage, F.H.; Mummery, C.L. Induced pluripotent stem cells: The new patient? Nat. Rev. Mol. Cell Biol. 2012, 13, 713–726. [CrossRef] [PubMed]
6. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872. [CrossRef] [PubMed]
7. Yu, J.; Vodyanik, M.A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.; Ruotti, V.; Stewart, R.; et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318, 1917–1920. [CrossRef] [PubMed]
8. Schlaeger, T.M.; Daheron, L.; Brickler, T.R.; Entwisle, S.; Chan, K.; Cianci, A.; DeVine, A.; Ettenger, A.; Fitzgerald, K.; Godfrey, M.; et al. A comparison of non-integrating reprogramming methods. Nat. Biotechnol. 2015, 33, 58–63. [CrossRef] [PubMed]
9. Martin, M.J.; Muotri, A.; Gage, F.; Varki, A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 2005, 11, 228–232. [CrossRef] [PubMed]
10. Takahashi, K.; Narita, M.; Yokura, M.; Ichisaka, T.; Yamanaka, S. Huma induced pluripotent stem cells on autologous feeders. PLoS ONE 2009, 4, e8067. [CrossRef] [PubMed]
11. Sugii, S.; Kida, Y.; Kawamura, T.; Suzuki, J.; Vassena, R.; Yin, Y.Q.; Lutz, M.K.; Berggren, W.T.; Izpisua Belmonte, J.C.; Evans, R.M. Human and mouseadipose-derived cells support feeder-independent induction of pluripotent stem cells. Proc.Natl.Acad.Sci.USA 2010, 107, 3558–3563. [CrossRef] [PubMed]
12. Du, S.H.; Tay, J.C.; Chen, C.; Tay, F.C.; Tan, W.K.; Li, Z.D.; Wang, S. Human iPS cell-derived fibroblast-like cells as feeder layers for iPS cell derivation and expansion. J.Biosci.Bioeng. 2015. [CrossRef] [PubMed]
13. Kim, H.T.; Lee, K.I.; Kim, D.W.; Hwang, D.Y. An ECM-based culture system for the generation and maintenance of xeno-free human iPS cells. Biomaterials 2013, 34, 1041–1050. [CrossRef] [PubMed]
14. Groß, B.; Sgodda, M.; Rasche, M.; Schambach, A.; Göhring, G.; Schlegelberger, B.; Greber, B.; Linden, T.; Reinhardt, D.; Cantz, T. Improved generation of patient-specific induced pluripotent stem cells using a chemically-defined and matrigel-based approach. Curr.Mol.Med. 2013, 13, 765–776. [CrossRef] [PubMed]
15. Sterneckert, J.L.; Reinhardt, P.; Schöler, H.R. Investigating human disease using stem cell models. Nat. Rev. Genet. 2014, 15, 625–639. [CrossRef] [PubMed]
16. Doetschman, T.C.; Eistetter, H.; Katz, M.; Schmidt, W.; Kemler, R. The in vitro development of blastocyst-derived embryonic stem cell lines: Formation of visceral yolk sac, blood islands and myocardium. J. Embryol. Exp. Morphol. 1985, 87, 27–45 [PubMed]
17. Imamura, T.; Cui, L.; Teng, R.; Johkura, K.; Okouchi, Y.; Asanuma, K.; Ogiwara, N.; Sasaki, K. Embryonic stem cell-derived embryoid bodies in three-dimensional culture system form hepatocyte-like cells in vitro and in vivo. Tissue Eng. 2004, 10, 1716–1724. [CrossRef] [PubMed]
18. Nakano, T.; Kodama, H.; Honjo, T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science 1994, 265, 1098–1101. [CrossRef] [PubMed]
19. Nishikawa, S.; Nishikawa, S.; Hirashima, M.; Matsuyoshi, N.; Kodama, H. Progressive lineage analysis by cell sorting and culture identifies FLK+VE-cadherin cells at a diverging point of endothelial and hemopoietic lineages. Development 1998, 125, 1747–1757 [PubMed]
20. Carpenter, L.; Carr, C.; Yang, C.T.; Stuckey, D.J.; Clarke, K.; Watt, S.M. Efficient differentiation of human induced pluripotent stem cells generates cardiac cells that provide protection following myocardial infarction in the rat. Stem Cells Dev. 2012, 21, 977–986. [CrossRef] [PubMed]
21. Giobbe, G.G.; Zagallo, M.; Riello, M.; Serena, E.; Masi, G.; Barzon, L.; di Camillo, B.; Elvassore, N. Confined 3D microenvironment regulates early differentiation in human pluripotent stem cells. Biotechnol. Bioeng. 2012, 109, 3119–3132. [CrossRef] [PubMed]
22. Takebe, T.; Sekine, K.; Enomura, M.; Koike, H.; Kimura, M.; Ogaeri, T.; Zhang, R.R.; Ueno, Y.; Zheng, Y.W.; Koike, N.; et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013, 499, 481–484. [CrossRef] [PubMed]
23. Dvir, T.; Timko, B.P.; Brigham, M.D.; Naik, S.R.; Karajanagi, S.S.; Levy, O.; Jin, H.; Parker, K.K.; Langer, R.; Kohane, D.S. Nanowired three-dimensional cardiac patches. Nat. Nanotechnol. 2011, 6, 720–725. [CrossRef] [PubMed]
24. Choi, S.H.; Kim, Y.H.; Hebisch, M.; Sliwinski, C.; Lee, S.; D’Avanzo, C.; Chen, H.; Hooli, B.; Asselin, C.; Muffat, J.; et al. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature 2014, 515, 274–278. [CrossRef] [PubMed]
25. Park, I.H.; Arora, N.; Huo, H.; Maherali, N.; Ahfeldt, T.; Shimamura, A.; Lensch, M.W.; Cowan, C.; Hochedlinger, K.; Daley, G.Q. Disease-specific induced pluripotent stem cells. Cell 2008, 134, 877–886. [CrossRef] [PubMed]
26. Tiscornia, G.; Vivas, E.L.; Izpisúa Belmonte, J.C. Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells. Nat. Med. 2011, 17, 1570–1576. [CrossRef] [PubMed]
27. Moretti, A.; Bellin, M.; Welling, A.; Jung, C.B.; Lam, J.T.; Bott-Flügel, L.; Dorn, T.; Goedel, A.; Höhnke, C.; Hofmann, F. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N.Engl.J.Med. 2010, 363, 1397–1409. [CrossRef] [PubMed]
28. Itzhaki, I.; Maizels, L.; Huber, I.; Zwi-Dantsis, L.; Caspi, O.; Winterstern, A.; Feldman, O.; Gepstein, A.; Arbel, G.; Hammerman, H.; et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471, 225–229. [CrossRef] [PubMed]
29. Ma, D.; Wei, H.; Lu, J.; Ho, S.; Zhang, G.; Sun, X.; Oh, Y.; Tan, S.H.; Ng, M.L.; Shim, W.; et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur. Heart J. 2013, 34, 1122–1133. [CrossRef] [PubMed]
30. Egashira, T.; Yuasa, S.; Suzuki, T.; Aizawa, Y.; Yamakawa, H.; Matsuhashi, T.; Ohno, Y.; Tohyama, S.; Okata, S.; Seki, T.; et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc. Res. 2012, 95, 419–429. [CrossRef] [PubMed]
31. Lee, G.; Papapetrou, E.P.; Kim, H.; Chambers, S.M.; Tomishima, M.J.; Fasano, C.A.; Ganat, Y.M.; Menon, J.; Shimizu, F.; Viale, A.; et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009, 461, 402–406. [CrossRef] [PubMed]
32. Marchetto, M.C.; Carromeu, C.; Acab, A.; Yu, D.; Yeo, G.W.; Mu, Y.; Chen, G.; Gage, F.H.; Muotri, A.R. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143, 527–539. [CrossRef] [PubMed]
33. Devine, M.J.; Ryten, M.; Vodicka, P.; Thomson, A.J.; Burdon, T.; Houlden, H.; Cavaleri, F.; Nagano, M.; Drummond, N.J.; Taanman, J.W. Parkinson’s disease induced pluripotent stem cells with triplication of the _-synuclein locus. Nat.Commun. 2011, 2, e440. [CrossRef] [PubMed]
34. Brennand, K.J.; Simone, A.; Jou, J.; Gelboin-Burkhart, C.; Tran, N.; Sangar, S.; Li, Y.; Mu, Y.; Chen, G.; Yu, D.; et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473, 221–225. [CrossRef] [PubMed]
35. Israel, M.A.; Yuan, S.H.; Bardy, C.; Reyna, S.M.; Mu, Y.; Herrera, C.; Hefferan, M.P.; van Gorp, S.; Nazor, K.L.; Boscolo, F.S.; et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 2012, 482, 216–220. [CrossRef] [PubMed]
36. Rashid, S.T.; Corbineau, S.; Hannan, N.; Marciniak, S.J.; Miranda, E.; Alexander, G.; Huang-Doran, I.; Griffin, J.; Ahrlund-Richter, L.; Skepper, J.; et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J.Clin.Investig. 2010, 120, 3127–3136. [CrossRef] [PubMed]
37. Ghodsizadeh, A.; Taei, A.; Totonchi, M.; Seifinejad, A.; Gourabi, H.; Pournasr, B.; Aghdami, N.; Malekzadeh, R.; Almadani, N.; Salekdeh, G.H. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev. 2010, 6, 622–632. [CrossRef] [PubMed]
38. Serena, E.; Cimetta, E.; Zatti, S.; Zaglia, T.; Zagallo, M.; Keller, G.; Elvassore, N. Micro-arrayed human embryonic stem cells-derived cardiomyocytes for in vitro functional assay. PLoS ONE 2012, 7, e48483. [CrossRef] [PubMed]
39. Giobbe, G.G.; Michielin, F.; Luni, C.; Giulitti, S.; Martewicz, S.; Dupont, S.; Floreani, A.; Elvassore, N. Functional differentiation of human pluripotent stem cells on a chip. Nat. Methods 2015, 12, 637–640. [CrossRef] [PubMed]
40. Luni, C.; Michielin, F.; Barzon, L.; Calabrò, V.; Elvassore, N. Stochastic model-assisted development of efficient low-dose viral transduction in microfluidics. Biophys. J. 2013, 104, 934–942. [CrossRef] [PubMed]
41. Cimetta, E.; Franzoso, M.; Trevisan, M.; Serena, E.; Zambon, A.; Giulitti, S.; Barzon, L.; Elvassore, N. Microfluidic-driven viral infection on cell cultures: Theoretical and experimental study. Biomicrofluidics 2012, 6, 24127–2412712. [CrossRef] [PubMed]
42. Ding, Q.; Lee, Y.K.; Schaefer, E.A.; Peters, D.T.; Veres, A.; Kim, K.; Kuperwasser, N.; Motola, D.L.; Meissner, T.B.; Hendriks, W.T.; et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013, 12, 238–251. [CrossRef] [PubMed]
43. Gerna, G.; Baldanti, F.; Revello, M.G. Pathogenesis of human cytomegalovirus infection and cellular targets. Hum.Immunol. 2004, 65, 381–386. [CrossRef] [PubMed]
44. Goodrum, F.D.; Jordan, C.T.; High, K.; Shenk, T. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: A model for latency. Proc. Natl. Acad. Sci. USA 2002, 99, 16255–16260. [CrossRef] [PubMed]
45. Hargett, D.; Shenk, T.E. Experimental human cytomegalovirus latency in CD14+ monocytes. Proc. Natl. Acad. Sci. USA 2011, 107, 20039–20044. [CrossRef] [PubMed]
46. Ibanez, C.E.; Schrier, R.; Ghazal, P.; Wiley, C.; Nelson, J.A. Human cytomegalovirus productively infects primary differentiated macrophages. J.Virol. 1991, 65, 6581–6588 [PubMed]
47. Fish, K.N.; Soderberg-Naucler, C.; Mills, L.K.; Stenglein, S.; Nelson, J.A. Human cytomegalovirus persistently infects aortic endothelial cells. J. Virol. 1998, 72, 5661–5668 [PubMed]
48. Hahn, G.; Revello, M.G.; Patrone, M.; Percivalle, E.; Campanini, G.; Sarasini, A.; Wagner, M.; Gallina, A.; Milanesi, G.; Koszinowski, U.; et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 2004, 78, 10023–10033. [CrossRef] [PubMed]
49. Bentz, G.L.; Jarquin-Pardo, M.; Chan, G.; Smith, M.S.; Sinzger, C.; Yurochko, A.D. Human cytomegalovirus (HCMV) infection of endothelial cells promotes naive monocyte extravasation and transfer of productive virus to enhance hematogenous dissemination of HCMV. J. Virol. 2006, 80, 11539–11555. [CrossRef] [PubMed]
50. Weisblum, Y.; Panet, A.; Haimov-Kochman, R.; Wolf, D.G. Models of vertical cytomegalovirus (CMV) transmission and pathogenesis. Semin. Immunopathol. 2014, 36, 615–625. [CrossRef] [PubMed]
51. Griffiths, P.; Baraniak, I.; Reeves, M. The pathogenesis of human cytomegalovirus. J. Pathol. 2015, 235, 288–297. [CrossRef] [PubMed]
52. Cha, T.A.; Tom, E.; Kemble, G.W.; Duke, G.M.; Mocarski, E.S.; Spaete, R.R. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 1996, 70, 78–83 [PubMed]
53. Wang, D.; Shenk, T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc.Natl.Acad.Sci.USA 2005, 102, 18153–18158. [CrossRef] [PubMed]
54. Cosset, É.; Martinez, Y.; Preynat-Seauve, O.; Lobrinus, J.A.; Tapparel, C.; Cordey, S.; Peterson, H.; Petty, T.J.; Colaianna, M.; Tieng, V. Human three-dimensional engineered neural tissue reveals cellular and molecular events following cytomegalovirus infection. Biomaterials 2015, 53, 296–308.
55. Belzile, J.P.; Stark, T.J.; Yeo, G.W.; Spector, D.H. Human cytomegalovirus infection of human embryonic stem cell-derived primitive neural stem cells is restricted at several steps but leads to the persistence of viral DNA. J.Virol. 2014, 88, 4021–4039. [CrossRef] [PubMed]
56. D’Aiuto, L.; di Maio, R.; Heath, B.; Raimondi, G.; Milosevic, J.; Watson, A.M.; Bamne, M.; Parks, W.T.; Yang, L.; Lin, B.; et al. Human induced pluripotent stem cell-derived models to investigate human cytomegalovirus infection in neural cells. PLoS ONE 2012, 7, e49700. [CrossRef] [PubMed]
57. Lee, K.S.; Zhou, W.; Scott-McKean, J.J.; Emmerling, K.L.; Cai, G.Y.; Krah, D.L.; Costa, A.C.; Freed, C.R.; Levin, M.J. Human sensory neurons derived from induced pluripotent stem cells support varicella-zoster virus infection. PLoS ONE 2012, 7, e53010. [CrossRef] [PubMed]
58. D’Aiuto, L.; Prasad, K.M.; Upton, C.H.; Viggiano, L.; Milosevic, J.; Raimondi, G.; McClain, L.; Chowdari, K.; Tischfield, J.; Sheldon, M. Persistent infection by HSV-1 is associated with changes in functional architecture of iPSC-derived neurons and brain activation patterns underlying working memory performance. Schizophr.Bull. 2015, 41, 123–132. [CrossRef] [PubMed]
59. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012, 57, 167–185. [CrossRef] [PubMed]
60. Gripon, P.; Diot, C.; Guguen-Guillouzo, C. Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: Effect of polyethylene glycol on adsorption and penetration. Virology 1993, 192, 534–540. [CrossRef] [PubMed]
61. Khetani, S.R.; Bhatiam, S.N. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 2008, 26, 120–126. [CrossRef] [PubMed]
62. Shlomai, A.; Schwartz, R.E.; Ramanan, V.; Bhatta, A.; de Jong, Y.P.; Bhatia, S.N.; Rice, C.M. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc.Natl.Acad.Sci.USA 2014, 111, 12193–12198. [CrossRef] [PubMed]
63. Yan, H.; Zhong, G.; Xu, G.; He, W.; Jing, Z.; Gao, Z.; Huang, Y.; Qi, Y.; Peng, B.; Wang, H. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012, 1, e00049. [CrossRef] [PubMed]
64. Ko, C.; Park, W.J.; Park, S.; Kim, S.; Windisch, M.P.; Ryu, W.S. The FDA approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. Antivir. Ther. 2015, doi: 10.3851/IMP2965. [CrossRef][PubMed]
65. He, W.; Ren, B.; Mao, F.; Jing, Z.; Li, Y.; Liu, Y.; Peng, B.; Yan, H.; Qi, Y.; Sun, Y. Hepatitis D virus infection of mice expressing human sodium taurocholate co-transporting polypeptide. PLoS Pathog. 2015, 11, e1004840. [CrossRef] [PubMed]
66. Lavanchy, D. The global burden of hepatitis C. Liver Int. 2009, 29, 74–81. [CrossRef] [PubMed]
67. Kato, T.; Date, T.; Miyamoto, M.; Furusaka, A.; Tokushige, K.; Mizokami, M.; Wakita, T. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003, 125, 1808–1817. [CrossRef] [PubMed]
68. Lindenbach, B.D.; Evans, M.J.; Syder, A.J.; Wölk, B.; Tellinghuisen, T.L.; Liu, C.C.; Maruyama, T.; Hynes, R.O.; Burton, D.R.; McKeating, J.A. Complete replication of hepatitis C virus in cell culture. Science 2005, 309, 623–626. [CrossRef] [PubMed]
69. Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Kräusslich, H.G.; Mizokami, M., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat.Med. 2005, 11, 791–796. [CrossRef] [PubMed]
70. Heller, T.; Saito, S.; Auerbach, J.; Williams, T.; Moreen, T.R.; Jazwinski, A.; Cruz, B.; Jeurkar, N.; Sapp, R.; Luo, G., et al. An in vitro model of hepatitis C virion production. Proc.Natl.Acad.Sci.USA 2005, 102, 2579–2583. [CrossRef] [PubMed]
71. Kato, T.; Matsumura, T.; Heller, T.; Saito, S.; Sapp, R.K.; Murthy, K.; Wakita, T.; Liang, T.J. Production of infectious hepatitis C virus of various genotypes in cell cultures. J. Virol. 2007, 81, 4405–4411. [CrossRef] [PubMed]
72. Ploss, A.; Khetani, S.R.; Jones, C.T.; Syder, A.J.; Trehan, K.; Gaysinskaya, V.A.; Mu, K.; Ritola, K.; Rice, C.M.; Bhatia, S.N. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc. Natl. Acad. Sci. USA 2010, 107, 3141–3145. [CrossRef] [PubMed]
73. Podevin, P.; Carpentier, A.; Pène, V.; Aoudjehane, L.; Carrière, M.; Zaïdi, S.; Hernandez, C.; Calle, V.; Méritet, J.F.; Scatton, O., et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 2010, 139, 1355–1364. [CrossRef] [PubMed]
74. Thomas, E.; Gonzalez, V.D.; Li, Q.; Modi, A.A.; Chen, W.; Noureddin, M.; Rotman, Y.; Liang, T.J. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012, 142, 978–988. [CrossRef] [PubMed]
75. Mercer, D.F.; Schiller, D.E.; Elliott, J.F.; Douglas, D.N.; Hao, C.; Rinfret, A.; Addison, W.R.; Fischer, K.P.; Churchill, T.A.; Lakey, J.R., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat.Med. 2001, 7, 927–933. [CrossRef] [PubMed]
76. Tesfaye, A.; Stift, J.; Maric, D.; Cui, Q.; Dienes, H.P.; Feinstone, S.M. Chimeric mouse model for the infection of hepatitis B and C viruses. PLoS ONE 2013, 8, e77298. [CrossRef] [PubMed]
77. Wu, X.; Robotham, J.M.; Lee, E.; Dalton, S.; Kneteman, N.M.; Gilbert, D.M.; Tang, H. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog. 2012, 8, e1002617. [CrossRef] [PubMed]
78. Schwartz, R.E.; Trehan, K.; Andrus, L.; Sheahan, T.P.; Ploss, A.; Duncan, S.A.; Rice, C.M.; Bhatia, S.N. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc.Natl.Acad.Sci.USA 2012, 109, 2544–2548. [CrossRef] [PubMed]
79. Carpentier, A.; Tesfaye, A.; Chu, V.; Nimgaonkar, I.; Zhang, F.; Lee, S.B.; Thorgeirsson, S.S.; Feinstone, S.M.; Liang, T.J. Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J. Clin. Investig. 2014, 124, 4953–4964. [CrossRef] [PubMed]
80. Weglarz, T.C.; Degen, J.L.; Sandgren, E.P. Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes. Am. J. Pathol. 2000, 157, 1963–1974. [CrossRef]
81. Liu, H.; Kim, Y.; Sharkis, S.; Marchionni, L.; Jang, Y.Y. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci.Transl.Med. 2011, 3, 82-39. [CrossRef] [PubMed]
82. Moriguchi, H.; Chung, R.T.; Sato, C. An identification of novel therapy for human hepatocellular carcinoma by using human induced pluripotent stem cells. Hepatology 2010, 51, 1090–1091. [CrossRef] [PubMed]
83. Bowles, N.E.; Richardson, P.J.; Olsen, E.G.; Archard, L.C. Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986, 1, 1120–1123. [CrossRef]
84. Muehlenbachs, A.; Bhatnagar, J.; Zaki, S.R. Tissue tropism, pathology and pathogenesis of enterovirus infection. J. Pathol. 2015, 235, 217–228. [CrossRef] [PubMed]
85. Sharma, A.; Marceau, C.; Hamaguchi, R.; Burridge, P.W.; Rajarajan, K.; Churko, J.M.; Wu, H.; Sallam, K.I.; Matsa, E.; Sturzu, A.C., et al. Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform. Circ.Res. 2014, 115, 556–566. [CrossRef] [PubMed]
86. Sancho-Shimizu, V.; Perez de Diego, R.; Jouanguy, E.; Zhang, S.Y.; Casanova, J.L. Inborn errors of anti-viral interferon immunity in humans. Curr. Opin. Virol. 2011, 1, 487–496. [CrossRef] [PubMed]
87. Casrouge, A.; Zhang, S.Y.; Eidenschenk, C.; Jouanguy, E.; Puel, A.; Yang, K.; Alcais, A.; Picard, C.; Mahfoufi, N.; Nicolas, N., et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006, 314, 308–312. [CrossRef] [PubMed]
88. Zhang, S.Y.; Jouanguy, E.; Ugolini, S.; Smahi, A.; Elain, G.; Romero, P.; Segal, D.; Sancho-Shimizu, V.; Lorenzo, L.; Puel, A., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317, 1522–1527. [CrossRef] [PubMed]
89. Guo, Y.; Audry, M.; Ciancanelli, M.; Alsina, L.; Azevedo, J.; Herman, M.; Anguiano, E.; Sancho-Shimizu, V.; Lorenzo, L.; Pauwels, E., et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J.Exp.Med. 2011, 208, 2083–2098. [CrossRef] [PubMed]
90. Herman, M.; Ciancanelli, M.; Ou, Y.H.; Lorenzo, L.; Klaudel-Dreszler, M.; Pauwels, E.; Sancho-Shimizu, V.; Pérez de Diego, R.; Abhyankar, A.; Israelsson, E., et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J.Exp.Med. 2012, 209, 1567–1582. [CrossRef] [PubMed]
91. Lafaille, F.G.; Pessach, I.M.; Zhang, S.Y.; Ciancanelli, M.J.; Herman, M.; Abhyankar, A.; Ying, S.W.; Keros, S.; Goldstein, P.A.; Mostoslavsky, G., et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 2012, 491, 769–773. [CrossRef] [PubMed]
92. Ciancanelli, M.J.; Huang, S.X.; Luthra, P.; Garner, H.; Itan, Y.; Volpi, S.; Lafaille, F.G.; Trouillet, C.; Schmolke, M.; Albrecht, R.A., et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 2015, 348, 448–453. [CrossRef] [PubMed]
93. Barrangou, R.; Fremaux, C.; Deveau, H.; Richards, M.; Boyaval, P.; Moineau, S.; Romero, D.A.; Horvath, P. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315, 1709–1712. [CrossRef] [PubMed]
94. Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337, 816–821. [CrossRef] [PubMed]
95. Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraffini, L.A.; Zhang, F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339, 819–823. [CrossRef] [PubMed]
96. Cho, S.W.; Kim, S.; Kim, J.M.; Kim, J.S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013, 31, 230–232. [CrossRef] [PubMed]
97. Kim, H.; Kim, J.S. A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 2014, 15, 321–334. [CrossRef] [PubMed]
98. Qu, X.; Wang, P.; Ding, D.; Li, L.; Wang, H.; Ma, L.; Zhou, X.; Liu, S.; Lin, S.; Wang, X., et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res. 2013, 41, 7771–7782. [CrossRef] [PubMed]
99. Ebina, H.; Misawa, N.; Kanemura, Y.; Koyanagi, Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep. 2013, 3, e2510. [CrossRef] [PubMed]
100. Hu, W.; Kaminski, R.; Yang, F.; Zhang, Y.; Cosentino, L.; Li, F.; Luo, B.; Alvarez-Carbonell, D.; Garcia-Mesa, Y.; Karn, J., et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc.Natl.Acad.Sci.USA 2014, 111, 11461–11466. [CrossRef] [PubMed]
101. Liao, H.K.; Gu, Y.; Diaz, A.; Marlett, J.; Takahashi, Y.; Li, M.; Suzuki, K.; Xu, R.; Hishida, T.; Chang, C.J., et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat.Commun. 2015, 6, e6413. [CrossRef] [PubMed]
102. Ni, Z.; Knorr, D.A.; Clouser, C.L.; Hexum, M.K.; Southern, P.; Mansky, L.M.; Park, I.H.; Kaufman, D.S. Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms. J. Virol. 2011, 85, 43–50. [CrossRef] [PubMed]
103. Ni, Z.; Knorr, D.A.; Bendzick, L.; Allred, J.; Kaufman, D.S. Expression of chimeric receptor CD4_ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells 2014, 32, 1021–1031. [CrossRef] [PubMed]
104. Kamata, M.; Liu, S.; Liang, M.; Nagaoka, Y.; Chen, I.S. Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter. Hum. Gene Ther. 2010, 21, 1555–1567. [CrossRef] [PubMed]
105. Kambal, A.; Mitchell, G.; Cary, W.; Gruenloh, W.; Jung, Y.; Kalomoiris, S.; Nacey, C.; McGee, J.; Lindsey, M.; Fury, B., et al. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol.Ther. 2011, 19, 584–593. [CrossRef] [PubMed]
106. Anderson, J.S.; Javien, J.; Nolta, J.A.; Bauer, G. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 _ protein, a CCR5 shRNA, and a TAR decoy. Mol.Ther. 2009, 17, 2103–2114. [CrossRef] [PubMed]
107. Ye, L.; Wang, J.; Beyer, A.I.; Teque, F.; Cradick, T.J.; Qi, Z.; Chang, J.C.; Bao, G.; Muench, M.O.; Yu, J., et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5_32 mutation confers resistance to HIV infection. Proc.Natl.Acad.Sci.USA 2014, 111, 9591–9596. [CrossRef] [PubMed]
108. Jerebtsova, M.; Kumari, N.; Xu, M.; de Melo, G.B.; Niu, X.; Jeang, K.T.; Nekhai, S. HIV-1 resistant CDK2-knockdown macrophage-like cells generated from 293T cell-derived human induced pluripotent stem cells. Biology 2012, 1, 175–195. [CrossRef] [PubMed]
109. Yang, F.; Robotham, J.M.; Nelson, H.B.; Irsigler, A.; Kenworthy, R.; Tang, H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 2008, 82, 5269–5278. [CrossRef] [PubMed]
110. Seeger, C.; Sohn, J.A. Targeting hepatitis B virus with CRISPR/Cas9. Mol.Ther.Nucleic Acids 2014, 3, e216. [CrossRef] [PubMed]